Description: Botulinum neurotoxin A (BoNT-A), often referred to as ‘Botox’, is commonly used to treat medical conditions and increasingly in cosmetic procedures. However, long-term use and high doses of BoNT-A may lead to immunoresistance, limiting its future therapeutic benefit. A panel of experts including Dr Mary Dingley, Cosmetic Medicine Centre, Australia, is addressing this emerging issue. Its published recommendations offer a set of guidance for aesthetic practitioners to minimise the risk of immunoresistance. The panel also promotes a culture of open communication with patients about BoNT-A risks, to empower individuals to make a fully informed decision.
